Interestingly, the syngeneic murine tumor model shown substantial sensitivity to anti-CTLA-4 immunotherapy, wherein our plant-produced anti-CTLA-4 was as sensitive as the commercial anti-CTLA-4 in suppressing growth of tumors positive for PD-L1 expression. Here, CTLA4 is linked to neoplasm.